Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.
Saved in:
| Title: | Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. |
|---|---|
| Authors: | Phillips R; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland., Shi WY; Stanford Cancer Institute, Department of Radiation Oncology, School of Medicine, Stanford University, Stanford, California., Deek M; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland., Radwan N; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland., Lim SJ; Department of Medical Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland., Antonarakis ES; Department of Medical Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland., Rowe SP; The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland.; The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland., Ross AE; The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland., Gorin MA; The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland.; The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland., Deville C; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland., Greco SC; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland., Wang H; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland., Denmeade SR; Department of Medical Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland., Paller CJ; Department of Medical Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland., Dipasquale S; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland., DeWeese TL; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.; Department of Medical Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.; The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland., Song DY; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.; Department of Medical Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.; The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland., Wang H; Department of Medical Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland., Carducci MA; Department of Medical Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland., Pienta KJ; Department of Medical Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.; The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland., Pomper MG; The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland.; The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland., Dicker AP; Sidney Kimmel Cancer Center, Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania., Eisenberger MA; Department of Medical Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland., Alizadeh AA; Stanford Cancer Institute, Division of Oncology, Department of Medicine, School of Medicine, Stanford University, Stanford, California., Diehn M; Stanford Cancer Institute, Department of Radiation Oncology, School of Medicine, Stanford University, Stanford, California., Tran PT; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.; Department of Medical Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.; The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland. |
| Source: | JAMA oncology [JAMA Oncol] 2020 May 01; Vol. 6 (5), pp. 650-659. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
